Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | BRAF |
| Variant | L584P |
| Impact List | missense |
| Protein Effect | unknown |
| Gene Variant Descriptions | BRAF L584P lies within the protein kinase domain of the Braf protein (UniProt.org). L584P has been identified in the scientific literature (PMID: 31569065), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Dec 2025). |
| Associated Drug Resistance | |
| Category Variants Paths |
BRAF mutant BRAF L584P |
| Transcript | NM_004333.6 |
| gDNA | chr7:g.140753384A>G |
| cDNA | c.1751T>C |
| Protein | p.L584P |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_001354609.1 | chr7:g.140753384A>G | c.1751T>C | p.L584P | RefSeq | GRCh38/hg38 |
| NM_001354609.2 | chr7:g.140753384A>G | c.1751T>C | p.L584P | RefSeq | GRCh38/hg38 |
| NM_004333.6 | chr7:g.140753384A>G | c.1751T>C | p.L584P | RefSeq | GRCh38/hg38 |
| NM_001378470.1 | chr7:g.140753282_140753283delTTinsCC | c.1750_1751delTTinsCC | p.L584P | RefSeq | GRCh38/hg38 |
| NM_001378474.1 | chr7:g.140753384A>G | c.1751T>C | p.L584P | RefSeq | GRCh38/hg38 |
| NM_001378468.1 | chr7:g.140753384A>G | c.1751T>C | p.L584P | RefSeq | GRCh38/hg38 |
| NM_004333.5 | chr7:g.140753384A>G | c.1751T>C | p.L584P | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRAF G469A BRAF L584P | melanoma | predicted - sensitive | Dabrafenib + Trametinib | Case Reports/Case Series | Actionable | In a clinical case study, Mekinist (trametinib) and Tafinlar (dabrafenib) combination treatment resulted in decrease in metastatic lesions and a partial response with 94% reduction at three months and continued metabolic response at six months in a patient with metastatic melanoma harboring BRAF G469A and BRAF L584P (PMID: 31569065). | 31569065 |